Amgen Stock News
$261.43
11.08%
today
NYSE,
Nov 26, 05:15 pm CET
Amgen Stock News
Neutral
PRNewsWire
●
about 5 hours ago
THOUSAND OAKS, Calif. , Nov. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m.
AD HOC NEWS
●
about 18 hours ago
Die Aktien von Amgen US0311621009 sind am Dienstag nach Studiendaten zum Abnehmmittel Maritide auf Talfahrt gegangen.
Neutral
The Motley Fool
●
4 days ago
Investing in Pharma Stocks? Check These 3 Things First
Neutral
Reuters
●
5 days ago
Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might measure up against the popular GLP-1 drugs sold by Eli Lilly and Novo Nordisk.
Neutral
PRNewsWire
●
6 days ago
Howard Chang, M.D., Ph.D., Joins as Senior Vice President of Research and Chief Scientific Officer THOUSAND OAKS, Calif.
Negative
Investors Business Daily
●
7 days ago
With the recent spike in implied volatility, an iron condor on Amgen can use short strikes with a wide profit range. The post Amgen Stock Has High Implied Volatility.
Neutral
Seeking Alpha
●
8 days ago
Amgen's stock dropped nearly 15% last week due to safety concerns about its GLP-1 candidate MariTide. Amgen's management and analysts downplayed the bone mineral density concerns, emphasizing MariTide's potential and its ongoing Phase II study, which will be reported soon. Amgen's Q3 earnings call highlighted MariTide's promise, with plans for a broad Phase III program targeting obesity and typ...
Positive
The Motley Fool
●
10 days ago
Its future is bright, but that doesn't mean it'll always be smooth sailing.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
